Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials.

The article discusses the relationship between triglyceride (TG) levels and cardiovascular disease (CVD) risk. While controlling elevated levels of low-density lipoprotein-cholesterol (LDL-C) is a common approach to preventing CVD, studies suggest that elevated TG levels are an independent risk factor for atherosclerotic CVD. However, previous clinical trials targeting TG reduction have not provided conclusive evidence of its impact on CVD risk. The article highlights the importance of measuring apolipoprotein B (apoB) levels, which can accurately assess the number of atherogenic lipoproteins, and suggests that reducing apoB-containing lipoproteins may be more effective in reducing CVD risk than solely reducing TG levels. The article also discusses the findings of recent trials on TG-lowering agents and their impact on CVD risk. [Extracted from the article]

Copyright of European Heart Journal is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)